BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Daxor Corporation (DXR) Announces Placement of Three BVA-100 Blood Volume Analyzers


6/21/2012 9:14:07 AM

NEW YORK, NY--(Marketwire - June 21, 2012) -

Daxor Corporation (NYSE MKT: DXR) (NYSE Amex: DXR), an investment company with medical instrumentation and biotechnology operations, today announced the placement of Daxor's BVA-100 Blood Volume Analyzers in Temple University Hospital (TUH) and in two other hospitals. TUH is a 740-bed Philadelphia hospital and is one of the nation's premier academic medical centers and has been listed among the best in 13 specialties by US News & World Report. The other two hospitals each have more than 1,000 hospital beds. One is in the state of Minnesota and one is in the state of Florida. Both of these hospitals are interested in using the BVA-100 in treating their congestive heart failure patients. The identities of the two hospitals will be made some time after the instruments are installed.

Medicare has issued regulations which will penalize hospitals who readmit congestive heart failure patients in under 30 days. This regulation will be implemented in January 2013 and will provide a significant incentive for hospitals to optimize treatment of the congestive heart failure patients.

According to recent statistics 24.8% of congestive heart failure patients are readmitted for hospitalization within 30 days after being discharged. Treatment of congestive heart failure patients is the #1 expense for Medicare for patients over the age of 65.

Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com.


Daxor Contact Information:
Richard Dunn
Director of Operations
212-330-8502
rdunn@daxor.com

Diane Meegan
Investor Relations
212-330-8512
dmeegan@daxor.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES